Trial Profile

Phase I/II study of intra-arterial gemcitabine (RenovoCath) in patients with pancreatic cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 06 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Feb 2026 According to a RenovoRx media release,the company announced announced that a clinical data abstract submission by cancer experts at Moffitt Cancer Center to the 2026 Society of Interventional Radiology (SIR) Annual Scientific Meeting has been accepted.The meeting will be held April 11-15 2026,in Toronto, Ontario.
08 Jul 2024 According to a RenovoRx media release, data from this trial will be published in the International Peer-Reviewed Journal, The Oncologist and expected in the Summer 2024 issue.
17 Nov 2022 According to a RenovoRx media release, data from the trial were presented at the Advanced Interventional Management Symposium (AIMsymposium).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com